4 Pharmaceutical Stocks to Buy Now

by Portfolio Grader | March 8, 2013 1:00 pm

This week, four Pharmaceutical stocks are improving their overall rating on Portfolio Grader[1]. Each of these rates an “A” (“strong buy”) or “B” overall (“buy”).

This week, Repros Therapeutics (NASDAQ:RPRX[2]) is making solid headway. The company’s rating improves to an A (“strong buy”) from last week’s B (“buy”) rating. Repros Therapeutics is a development stage biopharmaceutical company focusing on the development of oral small molecule drugs for major unmet medical needs. For more information, get Portfolio Grader’s complete analysis of RPRX stock[3].

Johnson & Johnson (NYSE:JNJ[4]) earns an A this week, jumping up from last week’s grade of B. Johnson & Johnson manufactures health care products and provides related services for the consumer, pharmaceutical, and medical devices and diagnostics markets. The stock’s dividend yield is 2.4%. For more information, get Portfolio Grader’s complete analysis of JNJ stock[5].

This week, Bristol-Myers Squibb (NYSE:BMY[6]) is showing significant improvement as the company’s rating hops from a C (“hold”) to a B (“buy”). Bristol-Myers Squibb is a global company that develops, produces and sells pharmaceutical products. For more information, get Portfolio Grader’s complete analysis of BMY stock[7].

Watson Pharmaceuticals (NYSE:WPI[8]) shows solid improvement this week. The company’s rating rises from a B to an A. Watson develops, manufactures, markets, sells and distributes pharmaceutical products. For more information, get Portfolio Grader’s complete analysis of WPI stock[9].

Louis Navellier’s proprietary Portfolio Grader[10] stock ranking system assesses roughly 5,000 companies every week based on a number of fundamental and quantitative measures. Stocks are given a letter grade based on their results — with A being “strong buy,” and F being “strong sell.” Explore the tool here[11].

Source URL: https://investorplace.com/2013/03/4-pharmaceutical-stocks-to-buy-now-rprx-jnj-bmy-2/

---